July 9, 2018 - ZikaPLAN’s NEURO-ZIKA neurological manifestations working group leader, the University of Liverpool, has been working with another working group member, Fiocruz, and the Brazilian Ministry of Health, the Brazilian charities ‘Uniao de Maes dos Anjos-UMA’ (Recife), ‘Associação ... Read more
July 3, 2018 - NEURO-ZIKA pathogenesis work in ZikaPLAN is differentiating autoimmune versus direct neuropathic phenomena of ZIKV to impact both clinical care and basic understanding of disease. Read more
June 27, 2018 - Over 80% of the world’s population is at risk from vector-borne diseases, yet no single, all-encompassing resource for the researchers and health workers involved in vector-borne disease control exists today. The aim of the Global Vector ... Read more
June 14, 2018 - ZIKAlliance, ZikaPLAN, ZIKAction, and ZIKAVAX - the four EU-funded consortia - participated and presented their research findings at the International Symposium on Zika Virus Research, held in Marseille, France, between 4 and 6 June 2018. Importantly, ... Read more
Pettersson et al. – Emerging Microbes & Infections, May 2018
Zika virus (ZIKV) has attracted much attention globally, primarily because of its association with microcephaly in newborn babies, Guillain-Barre syndrome, acute disseminated encephalomyelitis in adults and transmission via the oral and sexual route. Much attention has been focused on the clinical symptoms, emergence, epidemiology and evolution of ZIKV in the Pacific region and the Americas. However, during 2016 and 2017, many new sequences were submitted from regions in Asia where there had been few previous reports of the presence of ZIKV.
Defining the spectrum of neurological diseases associated with Zika virus (ZIKV) infection, in both the central nervous system (CNS) and peripheral nervous system (PNS) of adults and children.
To protect pregnant women, novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of clothing and other wearable repellent technologies are being developed using new microencapsulation techniques.
Identifying the major T-cell epitopes and cross reactive B-cell epitopes on ZIKV and assessing the role of flavivirus antibodies in protective and pathogenic immunity following ZIKV through antibody dependent enhancement (ADE).
ZikaPLAN has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734584.